ClinicalTrials.gg
CompletedNCT01438489Updated Oct 7, 2016Results posted

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

A Phase 2 interventional study of Anifrolumab 300 mg and Anifrolumab 1000 mg in Systemic Lupus Erythematosus, sponsored by MedImmune LLC. Completed at 79 sites in 14 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-07.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
2nd of 20
626 · median 159
Started
2012
with 1 other
Phase 2
6 of 20
2 open now
Registered
1st of 20
by date
Lead sponsor
2 of 20
MedImmune LLC

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 2nd largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 1st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with chronic, moderately-to-severely active systemic lupus erythematosus (SLE) with an inadequate response to standard of care treatment for SLE.

Read the detailed description

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of 2 intravenous (IV) treatment regimens in adult participants with chronic, moderately-to-severely active SLE with an inadequate response to SOC SLE. The investigational product (anifrolumab or placebo) will be administered as a fixed dose every 4 weeks (28 days) for a total of 13 doses.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • MEDI-546
  • Anifrolumab
  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfills at least 4 of the 11 American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) including a positive antinuclear antibody (ANA) greater than or equal to 1:80 or elevated anti-double-stranded DNA or anti-Smith antibody at screening
  • Pediatric or adult SLE with chronic disease activity for greater than or equal to 24 weeks
  • Weight greater than or equal to 40 kg
  • Currently receiving stable dose of oral prednisone (or equivalent) less than or equal to 40 mg/day and/or antimalarials/immunosuppressives
  • Active moderate to severe SLE disease based on SLE disease activity score (SLEDAI) and British Isles Lupus Assessment Group Index (BILAG) and Physicians Global Assessment
  • No evidence of cervical on Pap smear within 2 years of randomization
  • Female participants must be willing to avoid pregnancy
  • Negative tuberculosis (TB) test or newly positive TB test due to latent TB for which treatment must be initiated at or before randomization.

Exclusion criteria

Exclusion Criteria:

  • Active severe SLE-driven renal disease or unstable renal disease prior to screening
  • Active severe or unstable neuropsychiatric SLE
  • active infection including ongoing and chronic infections
  • History of (HIV)
  • Confirmed Positive tests for or positive test for
  • History of severe herpes infection such as herpes encephalitis, ophthalmic herpes, disseminated herpes
  • Live or attenuated vaccine within 4 weeks prior to screening
  • Participants with significant hematologic abnormalities.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
626 participants (actual)

Study arms

  • Experimental
    Anifrolumab (MEDI-546) 300 mg

    Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

    Biological: Anifrolumab 300 mg

  • Experimental
    Anifrolumab (MEDI-546) 1000 mg

    Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

    Biological: Anifrolumab 1000 mg

  • Placebo comparator
    Matching Placebo

    Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.

    Other: Placebo

Interventions

  • Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

    Also known as: MEDI-546

  • Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

    Also known as: MEDI-546

  • OtherPlacebo

    Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169

    An SRI (4) responder defined as a participant who had 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of greater than or equal to (\>=) 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index 'A' organ system score and no more than one new or worsening BILAG-2004 Index 'B' organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.

    Time frame: Day 169

  2. Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169

    Type I IFN signature in whole blood assessed by using a 4-gene diagnostic test. The blood samples collected were to be used to prospectively identify participants as IFN test-high or test-low. The results of this test were used to stratify participants. An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 mg/day and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.

    Time frame: Day 169

Secondary outcomes

  1. Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 365

    An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the MDGA (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 281 through Day 365 (less than 10 mg/day and less or equal to the dose received on Day 1). SRI was analyzed by a logistic regression model.

    Time frame: Day 365

  2. Percentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 365

    Participants on OCS \>=10 mg/day of prednisone or equivalent at baseline who were able to taper to \<= 7.5 mg/day at Day 365 were evaluated.

    Time frame: Day 365

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A serious AE (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly (in offspring of participant). AEs may be treatment emergent (TE) \[that is, occurring after initial receipt of investigational product\] or non-TE. An AESI is one of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by investigator to sponsor.

    Time frame: Day 1 (Baseline) to Day 422 (End of Study)

  4. Number of Participants With Clinically Significant Laboratory Abnormalities in Investigations Reported as Treatment-Emergent Adverse Events

    Any medically significant change in laboratory evaluations were recorded as Treatment emergent adverse events.

    Time frame: Day 1 (Baseline) to Day 422 (End of Study)

  5. Number of Participants With Vital Signs Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

    Vital sign parameters are temperature, blood pressure, respiratory rate, heart rate and weight. Vital signs abnormalities were reported as TEAEs.

    Time frame: Day 1 (Baseline) to Day 422 (End of Study)

  6. Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

    Any medically significant changes from the screening ECG was recorded as TEAEs. An abnormal ECG findings such as QT prolonged were reported as treatment emergent adverse events.

    Time frame: Day 1 (Baseline) to Day 422 (End of Study)

  7. Percentage of SLE Participants With Positive Anti-drug Antibody (ADA)

    Anti-drug antibody responses to anifrolumab in serum were evaluated.

    Time frame: Days 1, 85, 141, 169, 253, 337 (Treatment Phase), 365, 396, and 422 (Follow-up Period)

  8. Neutralization Ratio of 21-Gene Type I Interferon (IFN) Signature for Participants With Positive Baseline Pharmacodynamic (PD) Gene Signature

    The PD positive and negative gene signature was determined by comparing the expression of type I IFN-inducible genes in a 21-gene panel in study participants relative to pooled normal blood collected from healthy participants.

    Time frame: Days 29, 85, 141, 169, 253, 337 (treatment phase), on Days 365, 396, and 422 (follow up period)

  9. Maximum Observed Plasma Concentration (Cmax) of Anifrolumab at Day 1, 169 and 337

    Maximum plasma concentration (Cmax) was defined as the peak plasma level of anifrolumab, derived from plasma concentration -time data.

    Time frame: Pre-infusion and 15 minutes post-infusion on Day 1, 169 and 337

  10. Accumulation Ratio of Maximum Observed Plasma Concentration (Cmax,AR) of Anifrolumab

    Accumulation ratio for maximum plasma concentration (Cmax,AR) of anifrolumab after multiple administration at Day 169 and 337 was calculated.

    Time frame: Pre-infusion and 15 minutes post-infusion on Day 169 and 337

  11. Trough Concentration (Ctrough) of Anifrolumab at Day 29, 169 and 365

    Trough concentration (Ctrough) of anifrolumab at Day 29, 169 and 365 were calculated.

    Time frame: Pre-infusion and 15 minutes post-infusion on Day 29, 169 and 365

  12. Accumulation Ratio of Trough Concentration (Ctrough,AR) of Anifrolumab at Day 169 and 365

    Accumulation ratio for trough concentration (Ctrough,AR) of anifrolumab after multiple administration at Day 169 and 365 was calculated.

    Time frame: Pre-infusion and 15 minutes post-infusion on Day 169 and 365

07

Results

Posted Aug 15, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Started103100104
Completed778485
Not completed261619
Withdrew: Lost to follow-up422
Withdrew: Withdrawal by subject1138
Withdrew: Death001
Withdrew: Sponsor decision414
Withdrew: Subject choice/subject moved211
Withdrew: Investigator decision010
Withdrew: Ae/saes211
Withdrew: Received prohibited medication100
Withdrew: Did not complete all 3 follow-up visits252
Withdrew: Inadequate venous access020

Outcome measures

PrimaryPercentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169

An SRI (4) responder defined as a participant who had 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of greater than or equal to (\>=) 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index 'A' organ system score and no more than one new or worsening BILAG-2004 Index 'B' organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.

Time frame:
Day 169
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169
Percentage of ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 16917.634.328.8
Statistical analysis
  • Placebo vs Anifrolumab 300 mg · Regression, Logistic · p = 0.014 · Odds ratio (or): 2.38 · 90% CI 1.33 to 4.26
  • Placebo vs Anifrolumab 1000 mg · Regression, Logistic · p = 0.063 · Odds ratio (or): 1.94 · 90% CI 1.08 to 3.49
PrimaryPercentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169

Type I IFN signature in whole blood assessed by using a 4-gene diagnostic test. The blood samples collected were to be used to prospectively identify participants as IFN test-high or test-low. The results of this test were used to stratify participants. An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 mg/day and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.

Time frame:
Day 169
Reported as:
Number · Percentage of Participants
Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169
Percentage of ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 16913.23628.2
Statistical analysis
  • Placebo vs Anifrolumab 300 mg · Regression, Logistic · p = 0.004 · Odds ratio (or): 3.55 · 90% CI 1.72 to 7.32
  • Placebo vs Anifrolumab 1000 mg · Regression, Logistic · p = 0.029 · Odds ratio (or): 2.65 · 90% CI 1.27 to 5.53
SecondaryPercentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 365

An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the MDGA (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 281 through Day 365 (less than 10 mg/day and less or equal to the dose received on Day 1). SRI was analyzed by a logistic regression model.

Time frame:
Day 365
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 365
Percentage of ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 36525.551.538.5
SecondaryPercentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 365

Participants on OCS \>=10 mg/day of prednisone or equivalent at baseline who were able to taper to \<= 7.5 mg/day at Day 365 were evaluated.

Time frame:
Day 365
Reported as:
Number · Percentage of Participants
Percentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 365
Percentage of ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Percentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 36526.656.431.7
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A serious AE (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly (in offspring of participant). AEs may be treatment emergent (TE) \[that is, occurring after initial receipt of investigational product\] or non-TE. An AESI is one of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by investigator to sponsor.

Time frame:
Day 1 (Baseline) to Day 422 (End of Study)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
TEAEs788490
TESAEs191618
AESIs121015
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities in Investigations Reported as Treatment-Emergent Adverse Events

Any medically significant change in laboratory evaluations were recorded as Treatment emergent adverse events.

Time frame:
Day 1 (Baseline) to Day 422 (End of Study)
Reported as:
Number · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities in Investigations Reported as Treatment-Emergent Adverse Events
ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Neutrophil count increased013
Leukocytosis012
Leukopenia203
Neutropenia003
Anaemia002
Iron deficiency anaemia011
Lymphopenia002
Microcytic anaemia102
Thrombocytosis010
White blood cell count increased001
Monocyte count increased001
Hypochromic anaemia100
Hyperglycaemia131
Hypokalaemia230
Hepatic enzyme increased103
Hypocalcaemia011
Lipid metabolism disorder011
Alanine aminotransferase increased011
Aspartate aminotransferase increased020
Blood creatine phosphokinase increased011
Hyperlipidaemia101
Hypertriglyceridaemia210
Hyponatraemia001
Blood alkaline phosphatase increased010
Gamma-glutamyltransferase increased010
Glomerular filtration rate decreased010
Transaminases increased101
Dyslipidaemia100
Alanine aminotransferase abnormal100
Aspartate aminotransferase abnormal100
Blood triglycerides abnormal100
Glomerular filtration rate increased100
SecondaryNumber of Participants With Vital Signs Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

Vital sign parameters are temperature, blood pressure, respiratory rate, heart rate and weight. Vital signs abnormalities were reported as TEAEs.

Time frame:
Day 1 (Baseline) to Day 422 (End of Study)
Reported as:
Number · Participants
Number of Participants With Vital Signs Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Hypertension732
Pyrexia503
Blood pressure increased021
Blood pressure decreased001
Hypotension010
Secondary hypertension001
Weight increased001
Blood pressure abnormal100
Chills100
Hypertensive emergency100
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

Any medically significant changes from the screening ECG was recorded as TEAEs. An abnormal ECG findings such as QT prolonged were reported as treatment emergent adverse events.

Time frame:
Day 1 (Baseline) to Day 422 (End of Study)
Reported as:
Number · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)002
SecondaryPercentage of SLE Participants With Positive Anti-drug Antibody (ADA)

Anti-drug antibody responses to anifrolumab in serum were evaluated.

Time frame:
Days 1, 85, 141, 169, 253, 337 (Treatment Phase), 365, 396, and 422 (Follow-up Period)
Reported as:
Number · Percentage of Participants
Percentage of SLE Participants With Positive Anti-drug Antibody (ADA)
Percentage of ParticipantsPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Day 1 (n=100,98,105)1.01.01.9
Day 85 (n=91,93,98)1.10.00.0
Day 141 (n=84,94,93)2.40.02.2
Day 169 (n=81,89,92)2.50.01.1
Day 253 (n=72,86,86)0.01.20.0
Day 337 (n=70,87,76)0.01.10.0
Day 365 (n=85,96,94)0.01.01.1
Day 396 (n=78,88,90)0.02.30.0
Day 422 (n=76,86,77)1.35.80.0
Any Visit Post Baseline (n= 99,98,102)3.05.12.0
SecondaryNeutralization Ratio of 21-Gene Type I Interferon (IFN) Signature for Participants With Positive Baseline Pharmacodynamic (PD) Gene Signature

The PD positive and negative gene signature was determined by comparing the expression of type I IFN-inducible genes in a 21-gene panel in study participants relative to pooled normal blood collected from healthy participants.

Time frame:
Days 29, 85, 141, 169, 253, 337 (treatment phase), on Days 365, 396, and 422 (follow up period)
Reported as:
Mean · Ratio
Neutralization Ratio of 21-Gene Type I Interferon (IFN) Signature for Participants With Positive Baseline Pharmacodynamic (PD) Gene Signature
RatioPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Day 29 (n= 68, 66, 73)-0.753 ± 44.67870.194 ± 40.02882.056 ± 16.108
Day 85 (n= 63, 62, 72)-5.412 ± 44.35472.639 ± 34.44379.350 ± 40.428
Day 141 (n= 59, 64, 68)-25.411 ± 78.39173.662 ± 36.68488.569 ± 10.364
Day 169 (n= 56, 60, 66)-17.122 ± 67.60377.364 ± 30.73388.126 ± 10.278
Day 253 (n= 50, 60, 61)-9.908 ± 49.82673.972 ± 41.26786.099 ± 15.615
Day 337 (n= 49, 59, 53)-13.784 ± 45.54179.363 ± 28.80387.811 ± 8.410
Day 365 (n= 58, 66, 68)-6.428 ± 50.35872.796 ± 35.55281.115 ± 53.121
Day 396 (n= 56, 61, 64)-22.106 ± 64.52911.510 ± 56.38572.291 ± 31.182
Day 422 (n= 53, 57, 55)-31.777 ± 70.173-0.836 ± 44.59637.532 ± 66.339
SecondaryMaximum Observed Plasma Concentration (Cmax) of Anifrolumab at Day 1, 169 and 337

Maximum plasma concentration (Cmax) was defined as the peak plasma level of anifrolumab, derived from plasma concentration -time data.

Time frame:
Pre-infusion and 15 minutes post-infusion on Day 1, 169 and 337
Reported as:
Mean · micrograms/milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Anifrolumab at Day 1, 169 and 337
micrograms/milliliter (mcg/mL)Anifrolumab 300 mgAnifrolumab 1000 mg
Day 1 (n=98,104)82.8 ± 64.5248 ± 79.9
Day 169 (n=86,87)110 ± 63.7375 ± 137
Day 337 (n=83,67)127 ± 64.6439 ± 140
SecondaryAccumulation Ratio of Maximum Observed Plasma Concentration (Cmax,AR) of Anifrolumab

Accumulation ratio for maximum plasma concentration (Cmax,AR) of anifrolumab after multiple administration at Day 169 and 337 was calculated.

Time frame:
Pre-infusion and 15 minutes post-infusion on Day 169 and 337
Reported as:
Median · Ratio
Accumulation Ratio of Maximum Observed Plasma Concentration (Cmax,AR) of Anifrolumab
RatioAnifrolumab 300 mgAnifrolumab 1000 mg
Day 169 (n=81,86)1.36 ± 63.71.43 ± 137
Day 337 (n=78,66)1.56 ± 64.61.76 ± 140
SecondaryTrough Concentration (Ctrough) of Anifrolumab at Day 29, 169 and 365

Trough concentration (Ctrough) of anifrolumab at Day 29, 169 and 365 were calculated.

Time frame:
Pre-infusion and 15 minutes post-infusion on Day 29, 169 and 365
Reported as:
Mean · microgram per milliliter
Trough Concentration (Ctrough) of Anifrolumab at Day 29, 169 and 365
microgram per milliliterAnifrolumab 300 mgAnifrolumab 1000 mg
Day 29 (n=95,99)7.95 ± 6.1746.8 ± 24.6
Day 169 (n=87,87)18.4 ± 12.9110 ± 60.5
Day 365 (n=83,71)23.6 ± 15.5154 ± 89.2
SecondaryAccumulation Ratio of Trough Concentration (Ctrough,AR) of Anifrolumab at Day 169 and 365

Accumulation ratio for trough concentration (Ctrough,AR) of anifrolumab after multiple administration at Day 169 and 365 was calculated.

Time frame:
Pre-infusion and 15 minutes post-infusion on Day 169 and 365
Reported as:
Median · Ratio
Accumulation Ratio of Trough Concentration (Ctrough,AR) of Anifrolumab at Day 169 and 365
RatioAnifrolumab 300 mgAnifrolumab 1000 mg
Day 169 (n=82,86)2.49 ± 63.72.29 ± 137
Day 365 (n=79,70)3.06 ± 64.63.02 ± 140

Adverse events

Collected over Day 1 (Baseline) to Day 422 (End of Study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—19/101 (18.8%)36/101 (35.6%)
Anifrolumab 300 mg—16/99 (16.2%)40/99 (40.4%)
Anifrolumab 1000 mg—18/105 (17.1%)46/105 (43.8%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders6/1013/993/105
Chest painGeneral disorders1/1010/993/105
InfluenzaInfections and infestations0/1012/991/105
PneumoniaInfections and infestations2/1012/992/105
Ischaemic strokeNervous system disorders2/1010/990/105
VasculitisVascular disorders2/1010/990/105
HeadacheNervous system disorders1/1010/992/105
GoitreEndocrine disorders0/1011/990/105
Retinal disorderEye disorders0/1011/990/105
Abdominal painGastrointestinal disorders0/1011/990/105
Most frequent other events
Most frequent other events
EventPlaceboAnifrolumab 300 mgAnifrolumab 1000 mg
Urinary tract infectionInfections and infestations11/10115/997/105
HeadacheNervous system disorders13/10112/9912/105
NasopharyngitisInfections and infestations4/10112/9912/105
Upper respiratory tract infectionInfections and infestations10/10112/9911/105
BronchitisInfections and infestations4/1017/999/105
DiarrhoeaGastrointestinal disorders4/1014/998/105

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized into the study.

Age, Continuous
Age, Continuous(Years)PlaceboAnifrolumab 300 mgAnifrolumab 1000 mgTotal
Mean39.2 ± 12.939.3 ± 12.040.8 ± 11.639.8 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAnifrolumab 300 mgAnifrolumab 1000 mgTotal
Female949499287
Male96520
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAnifrolumab 300 mgAnifrolumab 1000 mgTotal
American Indian or Alaskan Native0415
Asian133622
Black or African American12191041
Native Hawaiian or Other Pacific Islander0000
White413651128
Other363736109
Multiple category checked1102
Region of Enrollment
Region of Enrollment(Participants)PlaceboAnifrolumab 300 mgAnifrolumab 1000 mgTotal
BRAZIL3003
BULGARIA3249
COLOMBIA16101844
CZECH REPUBLIC1023
HUNGARY25310
INDIA2103
MEXICO47516
PERU15221350
POLAND1191232
ROMANIA1012
SOUTH KOREA3036
TAIWAN72312
UKRAINE741122
UNITED STATES OF AMERICA28382995
Baseline weight
Baseline weight(kilogram)PlaceboAnifrolumab 300 mgAnifrolumab 1000 mgTotal
Mean68.08 ± 18.9869.62 ± 17.0970.74 ± 17.2969.48 ± 17.79
08

Study locations

79 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    La Jolla, California, United States
  • Research Site
    La Palma, California, United States
  • Research Site
    Long Beach, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Palm Desert, California, United States
  • Research Site
    San Leandro, California, United States
  • Research Site
    Upland, California, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Palm Harbor, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Decatur, Georgia, United States
  • Research Site
    Stockbridge, Georgia, United States
  • Research Site
    Idaho Falls, Idaho, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Las Cruces, New Mexico, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Edmond, Oklahoma, United States
  • Research Site
    Tulsa, Oklahoma, United States
  • Research Site
    Memphis, Tennessee, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Spokane, Washington, United States
  • Research Site
    Rio de Janeiro, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Barranquilla, Colombia
  • Research Site
    Bogota, Colombia
  • Research Site
    Bucaramanga, Colombia
  • Research Site
    Chia, Colombia
  • Research Site
    Medellin, Colombia
  • Research Site
    Brno, Czech Republic
  • Research Site
    Praha 2, Czech Republic
  • Research Site
    Uherske Hradiste, Czech Republic
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Dantoli-Nagpur, India
  • Research Site
    Hyderabad, India
  • Research Site
    Mumbai, India
  • Research Site
    New Delhi, India
  • Research Site
    Pune, India
  • Research Site
    Secunderabad, India
  • Research Site
    Gwangjin-gu, Korea, Republic of
  • Research Site
    Gwangju, Korea, Republic of
  • Research Site
    Seodaemun-gu, Korea, Republic of
  • Research Site
    Suwon-si, Korea, Republic of
  • Research Site
    Guadalajara, Mexico
  • Research Site
    Leon, Mexico
  • Research Site
    Mexico, Mexico
  • Research Site
    Toluca, Mexico
  • Research Site
    Arequipa, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Bialystok, Poland
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Nadarzyn, Poland
  • Research Site
    Poznan, Poland
  • Research Site
    Brasov, Romania
  • Research Site
    Iasi, Romania
  • Research Site
    Targu Mures, Romania
  • Research Site
    Chiayi, Taiwan
  • Research Site
    Kaohsiung, Taiwan
  • Research Site
    Taichung, Taiwan
  • Research Site
    Taipei, Taiwan
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kyiv, Ukraine
  • Research Site
    Lugansk, Ukraine
  • Research Site
    Lviv, Ukraine
  • Research Site
    Ternopil, Ukraine
  • Research Site
    Vinnitsya, Ukraine
  • Research Site
    Vinnytsia, Ukraine
09

References and documents

Publications

  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗
  • Casey KA, Smith MA, Sinibaldi D, Seto NL, Playford MP, Wang X, Carlucci PM, Wang L, Illei G, Yu B, Wang S, Remaley AT, Mehta NN, Kaplan MJ, White WI. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021 Mar;73(3):459-471. doi: 10.1002/art.41518. Epub 2021 Feb 15. PubMed 32909675 ↗
  • Brohawn PZ, Streicher K, Higgs BW, Morehouse C, Liu H, Illei G, Ranade K. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures. Lupus. 2019 Nov;28(13):1524-1533. doi: 10.1177/0961203319885447. Epub 2019 Oct 29. PubMed 31660791 ↗
  • Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, Wang L, Illei GG, White WI. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018 Nov 22;5(1):e000286. doi: 10.1136/lupus-2018-000286. eCollection 2018. Erratum In: Lupus Sci Med. 2018 Dec 22;5(1):e000286corr1. doi: 10.1136/lupus-2018-000286corr1. PubMed 30538817 ↗
  • Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S; CD1013 Study Investigators. Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386. doi: 10.1002/art.39962. PubMed 28130918 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2011
First posted
Sep 22, 2011
Start
Jan 2012
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Aug 15, 2016
Last update
Oct 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01438489
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Jan 2012
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Aug 15, 2016
Last update
Oct 7, 2016

Study contacts

Warren Greth, MD
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion